Cullinan Therapeutics 在 ESMO 2024 上公布了 Zipalertinib 的 2b 期研究结果。 Cullinan Therapeutics presents promising Phase 2b study results for Zipalertinib at ESMO 2024.

Cullinan Therapeutics 在 ESMO 2024 会议上报告了其 Zipalertinib 关键 2b 期研究模块 C 的积极更新结果。 Cullinan Therapeutics reported positive updated results from the Module C of its pivotal Phase 2b study on Zipalertinib at the ESMO 2024 conference. 调查结果表明,该药物的功效和安全情况大有希望,表明其对治疗方案的潜在影响。 The findings suggest promising efficacy and safety profiles for the drug, indicating its potential impact on treatment options. 该公司旨在根据这一数据进一步推动其发展。 The company aims to further advance its development based on this data.

文章

Market Screener

TMCnet

Finanz Nachrichten

-- 显示更少 --

相关故事